Proton therapy for atypical meningiomas of Neuro-Oncology, 123(1), 123–128. http://doi.org/10.1007/s11060-015-1770-9 McDonald, M. W., Plankenhorn, D. A., McMullen, K. P., Henderson, Dropcho, E. J., Shah, V., & Cohen-Gadol, A. (2015). Proton therapy for atypical meningiomas. Journal This is the author's manuscript of article published in final edited form as: Mark W. McDonald, M.D.,1,5 David A. Plankenhorn, B.S., 1 Kevin P. McMullen, M.D., 1,5 Mark A. Henderson M.D., 1 Edward J. Dropcho, M.D., 3 Mitesh V. Shah, M.D., 2, 4 Aaron A. Cohen-Gadol, M.D., M.Sc. 2, 4 1 Department of Radiation Oncology, 2 Department of Neurological Surgery, 3 Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 4 Goodman Campbell Brain and Spine, Indianapolis, IN 5 Indiana University Health Proton Therapy Center, Bloomington, IN Keywords: meningioma; atypical; radiation; proton therapy Corresponding author: Mark W. McDonald, MD Winship Cancer Institute of Emory University Department of Radiation Oncology 1365 Clifton Road NE, Suite A1300 Atlanta, GA 30322 Office: 404.778.3473 Fax: 404.778.4139
[email protected] Dr. McDonald is now affiliated with the department of radiation oncology at Emory University. Dr. Henderson is now affiliated with the department of radiation oncology at Oregon Health and Science University. 1 Abstract We report clinical outcomes of proton therapy in patients with World Health Organization grade 2 (atypical) meningiomas. Between 2005 and 2013, 22 patients with atypical meningiomas were treated to a median dose of 63 Gy (RBE) using proton therapy, as an adjuvant therapy after surgery (n=12) or for recurrence or progression of residual tumor (n=10).